stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Return on equity
Alnylam Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 September 2026 was 138.1%, up 64.8 percentage points from fiscal 2025 (73.3%). Over the past ten years it has ranged from −526.1% (fiscal 2022) to 362.3% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 73.3% | (289.01) |
| FY2024 | 362.3% | 129.89 |
| FY2023 | 232.4% | 758.54 |
| FY2022 | −526.1% | (419.83) |
| FY2021 | −106.3% | (36.39) |
| FY2020 | −69.9% | (5.26) |
| FY2019 | −64.7% | (15.03) |
| FY2018 | −49.6% | (13.09) |
| FY2017 | −36.5% | 1.00 |
| FY2016 | −37.5% | (11.18) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | 138.1% |
| ASND Ascendis Pharma A/S compare | 118.4% |
| EXEL Exelixis, Inc. compare | 44.3% |
| BBIO BridgeBio Pharma, Inc. compare | 26.2% |
| INCY Incyte Corporation compare | 7.84% |
| JAZZ Jazz Pharmaceuticals PLC compare | 5.05% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| BNTX BioNTech SE Sponsored ADR compare | −8.29% |
| INSM Insmed, Inc. compare | −72.5% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ALNY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement